The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

2 型糖尿病、胰腺炎和癌症中的外分泌和内分泌胰腺

• 批准号: 10657634
• 负责人: Santhi Swaroop Vege
• 金额: $ 47.7万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10657634
• 关键词: Abdominal Pain; Admission activity; Ancillary Study; Awareness; Biological; Biological Markers; Biometry; Clinic; Clinic Activity; Clinical; Clinical Research; Communities; Consult; Diabetes Mellitus; Diagnosis; Discipline; Disease; Early Diagnosis; Enrollment; Environment; Epidemiology; Evaluation; Exocrine pancreas; Goals; Heterogeneity; Incidence; Infrastructure; Institution; Internet; Islets of Langerhans; Knowledge; Laboratories; Lead; Leadership; Life Expectancy; Link; Longitudinal cohort; Longitudinal cohort study; Malignant Neoplasms; Malignant neoplasm of pancreas; Measures; Medical; Modification; Morbidity - disease rate; Newly Diagnosed; Non-Insulin-Dependent Diabetes Mellitus; Outpatients; Pain; Pain management; Pancreas; Pancreatic Diseases; Pancreatitis; Participant; Patients; Productivity; Protocols documentation; Research; Research Infrastructure; Research Personnel; Research Support; Role; Salivary; Sample Size; Solid; Techniques; Training; Validation; acute pancreatitis; chronic pancreatitis; clinical phenotype; clinical practice; cohort; design; diagnostic tool; epidemiology study; experience; improved; mortality; prospective; recruit; stem; working group

PROJECT SUMMARY / ABSTRACT Since the inception of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium, the Mayo Clinic team has been an active participant, including leadership roles, in multiple initiatives. A key priority of the Consortium is the facilitation of mechanism-based research of chronic pancreatitis, pancreatogenic diabetes mellitus, and pancreatic cancer through systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. The goal of the Mayo Clinic team is to contribute meaningfully to the most useful longitudinal cohorts that will increase our understanding of clinical, epidemiological, and biological characterization of patients with these conditions. The primary longitudinal cohort initiatives (outlined in the PAR) to which Mayo Clinic will continue to contribute are PROCEED and NOD. Mayo Clinic investigators will also extend ancillary studies in PROCEED (salivary biomarkers and internet based pain management techniques for pain in chronic pancreatitis (IMPACT)) that leverage the extensive infrastructure in place. The Consortium has defined three Working Groups (WG) in which Mayo Clinic investigators contribute and provide leadership (chronic pancreatitis (CP), Type 3c diabetes mellitus (T3cDM); pancreatic cancer-DM WG. Our contribution includes solid accrual rates for these studies to date, and successful completion of one ancillary study by the PI, active participation in the design of the NOD cohort and subsequent modifications, and extending accrual for DETECT. Using the existing, highly productive infrastructure we have established, our Specific Aims are to: 1) Continue to prospectively enroll and expand accrual of 100 Mayo patients into the PROCEED cohort. Using the clinical research infrastructure in place, we will also enroll chronic pancreatitis patients and subjects into ancillary studies within the CPDPC that include, among others: salivary biomarkers, MINIMAP, and PAIR. 2) Continue to prospectively enroll and expand accrual of 1,322 newly diagnosed diabetes patients into the NOD study. 3) Continue to lead and extend prospective accrual of 60 Mayo participants into the DETECT study. To accomplish these aims, we will implement and identify new strategies to improve recruitment into the main studies as well as ancillary studies at Mayo Clinic while providing to the CPDPC the scientific, clinical and recruitment experience of our investigators.

项目总结/摘要 自慢性胰腺炎、糖尿病和胰腺癌研究（CPDPC）开始以来 联盟，马约诊所团队一直是一个积极的参与者，包括领导作用，在多个 举措该联盟的一个关键优先事项是促进慢性疾病的机制研究， 胰腺炎、胰源性糖尿病和胰腺癌，通过系统收集临床资料， 与生物标本相关的纵向队列研究中的措施。马约诊所团队的目标是 有助于有意义的最有用的纵向队列，这将增加我们对临床， 流行病学和具有这些病症的患者的生物学表征。主纵向 马约诊所将继续为PROCEED和 点头马约诊所的研究人员还将扩展PROCEED的辅助研究（唾液生物标志物和 基于互联网的慢性胰腺炎疼痛管理技术（IMPACT））， 广泛的基础设施。该联盟已经确定了三个工作组（WG），其中马约 临床研究者做出贡献并提供领导（慢性胰腺炎（CP）、3c型糖尿病 （T3 cDM）;胰腺癌-DM WG。我们的贡献包括迄今为止这些研究的可靠应计率， PI成功完成一项辅助研究，积极参与NOD队列的设计 以及后续的修改，并延长DETECT的应计费用。利用现有的高生产率 我们建立的基础设施，我们的具体目标是： 1)继续前瞻性入组100例马约患者，并将入组人数扩大至PROCEED队列。 利用现有的临床研究基础设施，我们还将招募慢性胰腺炎患者， 受试者进入CPDPC内的辅助研究，其中包括：唾液生物标志物， MINIMAP和PAIR。 2)继续前瞻性入组1，322例新诊断的糖尿病患者，并扩大入组范围， NOD研究。 3)继续领导并扩展60名马约受试者进入DETECT研究的前瞻性招募。 为达致这些目标，我们会推行和制订新策略，改善主要公务员的招聘工作， 研究以及马约诊所的辅助研究，同时向CPDPC提供科学、临床和 我们的调查人员的招聘经验。